NASDAQ
3.71USD
0.00 (0.00%)
We have scored 9 news catalysts on Evaxion Biotech A/S (EVAX) over the past 12 months. The biggest single-day move next to one of them came Nov 29, 2025, when EVAX closed +5.1%: “Brokerages Set Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) Price Target at $12.33”. Coverage across the window leans positive (average ticker sentiment +0.58). Most of the impact sits in short squeeze potential and sector healthcare.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
23.4M
P/E
—
EPS
—
Beta
0.27
52W range
2.72-6.92
Day range
3.60–3.73
Open
3.73
Prev close
3.71
Volume
107.6K
Avg volume
166.1K
Dividend
0.00
IPO
2021-02-05
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Evaxion Biotech A/S — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for EVAX: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Evaxion Biotech A/S is a clinical-stage biotechnology firm dedicated to creating artificial intelligence-driven immunotherapies. Its innovative pipeline targets cancers, bacterial infections, and viral diseases. The company's oncology portfolio features several promising candidates: EVX-01, a leading cancer immunotherapy currently in Phase IIb clinical trials for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy undergoing Phase IIa trials for adjuvant melanoma; and EVX-03, another DNA-based immunotherapy in development for a range of cancers. Beyond oncology, Evaxion is advancing three pre-clinical vaccine candidates—EVX-B1, EVX-B2, and EVX-V1—aimed at combating various bacterial and viral pathogens. Founded in 2008, Evaxion Biotech A/S is headquartered in Hørsholm, Denmark.
